<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418417</url>
  </required_header>
  <id_info>
    <org_study_id>1200/07</org_study_id>
    <nct_id>NCT01418417</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fasting Conditions</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delayed Release Tablets of Wyeth Pharmaceuticals Inc, in Healthy Human Adult Subjects, Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      Objective:

      To compare the single dose bioavailability of Torrent's Pantoprazole Sodium Delayed - Release
      Tablets 1 × 40 mg and PROTONIX® (Pantoprazole Sodium) Delayed - Release Tablets 1 × 40 mg of
      Wyeth Pharmaceutical Inc. Dosing periods were separated by a washout period of at least 7
      days.

      Study Design:

      randomized, open label, two treatment, two period, two sequence, single dose, crossover study
      in healthy human adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax parameter</measure>
    <description>bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based AUC parameter</measure>
    <description>bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUC(o-t).</description>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Pantoprazole Sodium Delayed - Release Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human adult subjects between 18-55 years of age (inclusive), having a body
             mass index (BMI) between 18 and 27 kg/m2.

          -  Subjects who have no evidence of underlying disease during screening history and whose
             physical examination is performed within 21 days prior to commencement of the study.

          -  Subjects whose screening laboratory values are within normal limits or considered by
             the physician/Principal Investigator to be of no clinical significance.

          -  Informed consent given in written form according to section 11.3 of the protocol.

          -  Female Subjects:

               1. Of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

               2. Postmenopausal for at least 1 year.

               3. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject).

        Exclusion Criteria:

          -  History or presence of significant:

               1. Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,
                  endocrine, immunologic, dermatologic, musculoskeletal, neurological or
                  psychiatric disease.

               2. Alcohol dependence, alcohol abuse or drug abuse within past one year.

               3. Moderate to heavy smoking (&gt;10 cigarettes/day) or consumption of tobacco
                  products.

               4. History of difficulty in swallowing tablet / capsule.

               5. Clinically significant illness within 4 weeks before the start of the study

               6. Asthma, urticaria or other allergic type reactions after taking any medication.

               7. Positive urine drug screening, HIV, Hepatitis B &amp; C tests.

               8. Any history of hypersensitivity to Pantoprazole Sodium.

               9. Existence of any surgical or medical condition, which, in the judgment of
                  clinical investigator might interfere with the pharmacokinetics of the drug or
                  likely to compromise the safety of the subject.

              10. Inability to communicate or co-operate with the investigator due to language
                  problem, attitude, poor mental development / impaired cerebral function.

          -  Subject who has participated in any other clinical trial involving drug administration
             and collection of blood samples or has donated blood in the preceding 12 weeks prior
             to the start of the study.

          -  Subjects who have:

               1. Systolic blood pressure less than 90 mm of Hg or more than 150 mm of Hg.

               2. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. 3) Minor
                  deviations (2-4 mm Hg) at check-in may be acceptable at the discretion of the
                  physician /investigator.

             4) Pulse rate below 50/minute or above 105/minute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lotus Labs Pvt. Ltd.</name>
      <address>
        <city>Bangalore,</city>
        <state>Karnataka,</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>August 15, 2011</last_update_submitted>
  <last_update_submitted_qc>August 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Investigator</name_title>
    <organization>Torrent Pharmaceuticals Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

